Chemotherapy and chemoradiotherapy for esophageal cancer

Critical Reviews in Oncology/Hematology

Volumn 28, Issue 3, 1998, Pages 173-180

  Ohtsu, Atsushi ^a   Yoshida, Shigeaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS CANCER; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0032168594     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00020-1     Document Type: Article

References (59)

1. Roth JA, Putnam JB Jr Surgery of cancer of the esophagus. Semin Oncol. 21:1994;453-461.
2. Parameters linked to 10-year survival in Japan of resected esophageal carcinoma. Chest. 96:1989;1005-1011.
3. Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamoous cell carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg. 114:1997;205-209.
4. Roth JA, Putnam JB, Rich TA et al. Cancer of the esophagus. Devita VT et al. Cancer; Principles and Practice of Oncology. Fifth:1997;980-1021 Lippincott-Raven, Philadelphia.
5. Ajani JA Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. Semin Oncol. 21:1994;474-482.
6. Kelsen D, Hilaris B, Coonley C et al. Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma: Eastern cooperative oncology group experience. Am J Med. 75:1983;645-652.
7. Dinwoodie WR, Bartorucci AA, Lyman GH et al. Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group trial. Cancer Treat Rep. 70:1986;267-270.
8. Hilgenberg AD, Carey RW, Wilkins EW et al. Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorc Surg. 45:1988;357-363.
9. Ajani JA, Ryan B, Rich TA et al. Prolonged chemotherapy for localized squamous cell carcinoma of the esophagus. Eur J Cancer. 28A:1992;880-884.
10. Mercke C, Albertsson M, Hambraeus G et al. Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Acta Oncolgica. 30:1991;617-622.
11. Scanlon K.J., Newman Y.L., Priest D.G. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 83:1986;8923-8925.
12. Byfield JE Combined modality infusional chemotherapy with radiation. Lokich JJ Cancer Chemotherapy by Infusion. 2nd edition:1990;521-551 Percepta Press, Chicago.
13. Douple EB, Richmond RC A review of interactions between platinum coordination complexes and ionizing radiation: implication for cancer therapy. Prestayko AW, Crooke ST, Karter SK Cisplatin; current status and new developments. 1980;125-147 Academic Press, Orland, FL.
14. Herskovic A, Martz K, Sarraf MA et al. Combined chemotherapy and radiotherapy in patients with cancer of the esophagus. New Engl J Med. 326:1992;1593-1598.
15. Coia LR Chemoradiation as primary management of esophageal cancer. Semin Oncol. 21:1994;483-492.
16. Earlham R, Cunhan-Melo JR Oesophageal squamous cell carcinoma. A critical review of surgery. Br J Surg. 67:1980;381-390.
17. Coia LR, Soffen EM, Schultheiss T Swallowing function in patients with esophageal carcinoma treated with concurrent radiation and chemotherapy. Cancer. 71:1993;281-286.
18. Gill PG, Denham JW, Jamieson CG et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiation. J Clin Oncol. 10:1992;1037-1043.
19. Wong J Esophageal resection for cancer: the rationale of current practice. Surgery. 153:1987;18-24.
20. Stewart FM, Harkins BJ, Halin SS et al. Cis-platin, 5-fluorouracil, mitomycin and concurrent radiation therapy with and without esohagectomy for esophageal carcinoma. Cancer. 64:1989;622-628.
21. Burmeister BH, Denham JW, O'Brien M et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Rad Oncol Biol Phys. 32:1995;997-1006.
22. Blot WJ, Devesa SS, Kneller RW et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc. 265:1991;1287-1289.
23. Ajani JA, Ilson DH, Daughetry K et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 86:1994;1086-1091.
24. Ajani JA, Ilson D, Bhala K et al. Taxol, cisplatin and 5FU: a multi-institutional phase II study in patients with carcinoma of the esophagus. Proc Am Soc Clin Oncol. 14:1995;489.
25. Javed T, Reed C, Walle T et al. A regimen of paclitaxel (P), cisplatin (CP) and 5-fluorouracil followed by G-CSF is highly active against epidermoid and adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol. 14:1995;456.
26. Ilson D, Arquette M, Costa F et al. Preoperative paclitaxel/cisplatin in esophageal carcinoma: a phase II multicenter trial. Proc Am Soc Clin Oncol. 16:1997;261a.
27. Costa F, Ilson D, Forastiere A et al. Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell carcinoma (S) of the esophagus. Proc Am Soc Clin Oncol. 16:1997;262a.
28. Einzig AI, Neuberg D, Remick SC et al. Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 13:1996;87-93.
29. Conroy T, Etienne PL, Adenis A et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. J Clin Oncol. 14:1996;164-170.
30. Taguchi T, Wakui A, Nabeya K et al. A phase II atudy of cis-diammine glycolate platinum, 254-S, for gastrointestinal cancers. Jpn J Cancer Chemother. 19:1992;483-488. In Japanese with English abstract.
31. Urba SG. Multimodality therapy of esophageal carcinoma. Proc Am Soc Clin Oncol (Educational Book). 15:1997;175-178.
32. Burris HA, Moore MJ, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 15:1997;2403-2413.
33. Shirao K, Shimada Y, Kondo H et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol. 15:1997;921-927.
34. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer. Proc Am Soc Clin Oncol. 16:1997;264a.
35. Becouam Y, Ychou M, Ducreux M et al. Oxaliplatin (L-OHP) as firstline chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol. 16:1997;2291.
36. Giacchetti S, Zidani R, Perpoint B et al. Phase III trial of 5-flourouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in patients (pts) with matastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol. 16:1997;264a.
37. Roussel A, Bleiberg H, Dalesio O et al. Palliative therapy of inoperable oesophageal carcinoma with radiotherapy and methotrexate: final results of a controlled clinical trial. Int J Radiat Oncol Biol Phys. 16:1989;67-72.
38. Araujo CMM, Souhami L, Gil RA et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer. 67:1991;2258-2261.
39. Sischy B, Ryan L, Haller D et al. Interim report of EST 1282 phase III protocol for the evaluation of combined modalities in the treatment of patients with carcinoma of the esophagus. Proc Am Soc Clin Oncol. 9:1990;105. Abstract.
40. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer. an intergroup study. J Clin Oncol. 15:1997;277-284.
41. Minsky BD, Neuberg D, Kelsen D et al. Neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol. 14:1996;149-155.
42. Minsky BD Nonsurgical treatment approaches for esophageal cancer. Proc Am Soc Clin Oncol (Educational Book). 14:1997;164-174.
43. Leichman L, Steiger Z, Seidel HG et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol. 2:1984;75-79.
44. Poplin E, Fleming T, Leichman L et al. Combined therapies for squamous cell carcinoma of the esophagus, a Southwest Oncology Study Group Study (SWOG-8037). J Clin Oncol. 5:1987;622-628.
45. Forastier AA, Orringer MB, Perez-Tamayo C et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 11:1993;1118-1123.
46. Nygaard K, Hagen S, Hansen HS et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized multicenter study of preoperative radiotherapy and chemotherapy. World J Surg. 16:1992;1104-1109.
47. Le Prise E, Etienne P, Meunier B et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 73:1994;1779-1784.
48. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med. 335:1996;462-467.
49. Wilke H, Fink U. Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. New Engl J Med. 335:1996;509-510.
50. Urba S, Orringer M, Turrisi A et al. A randomized trial comparing transhiatal esophagectomy to preoperative concurrent chemoradiation followed by esophagectomy in locoregional esophageal carcinoma. Proc Am Soc Clin Oncol. 14:1995;199.
51. Urba S, Orringer M, Turrisi A et al. A randomized trial comparing surgery (S) to preoperative concomitant chemoradiation plus surgery in patients (pts) with resectable esophageal cancer (CA): updated analysis. Proc Am Soc Clin Oncol. 16:1997;277a.
52. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Eng J Med. 337:1997;161-167.
53. Ohtsu A, Yoshida S, Boku N et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol. 25:1995;261-266.
54. Meluch AA, Hainsworth JD, Thomas M et al. Preoperative therapy with paclitaxel, carboplatin, 5-FU and radiation yields 69% pathologic complete response (CR) rate in the treatment of local esophageal carcinoma. Proc Am Soc Clin Oncol. 16:1997;261a.
55. Jager JJ, Pannebakker M, Rijken J et al. Palliation in esophageal cancer with a single session of intraluminal irradiation. Radiother Oncol. 25:1992;134-136.
56. Hareyama M, Nishio M, Kagami Y et al. Intracavitary brachytherapy combined with external-beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys. 24:1992;235-240.
57. Nishimura Y, Ono K, Tsutsui K et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys. 30:1994;1099-1105.
58. Adelstein DJ, Rice TW, Becker M et al. Accelerated hyperfractionationradiation (AFR), concurrent cisplatin (DDP)/paclitaxel (TAX) chemotherapy (CT) and surgery for locoregionally advanced esophageal cancer. Proc Am Sco Clin Oncol. 16:1997;260a.
59. Raoul JL, Le Prise E, Meunier B et al. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Proc Am Sco Clin Oncol. 16:1997;261a.